CD27 and neoplasm: Following promising results of a pre-clinical study demonstrating that anti-CD27 and anti-CD20 mAb in combination induced robust anti-tumor efficacy in pre-clinical B-cell lymphoma models (118), another clinical study was designed where Varlilumab was combined with the anti-CD20 antibody Rituximab to test efficacy in relapsed or refractory B-cell lymphoma.